AMNOG price negotiations

Based on the benefit assessment resolution of the Federal Joint Committee (G-BA), the negotiations of the reimbursement price with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) will start subsequently. Besides legal and formal criteria, in these negotiations, various factors will have an impact on the negotiation of the reimbursement price, not all of which are entirely within the control of the pharmaceutical entrepreneur and have to be taken into account for the entrepreneur's own negotiation strategy. 

Ecker + Ecker offers strategic and operational support in the price negotiations and arbitration proceedings with various tools and services:

Price negotiation strategy

  • Strategy development
  • Stress testing of existing strategies
  • Roadmap for the negotiation
  • Ongoing negotiation support

Pricing analyses

  • Market environment analyses
  • Interactive tools for calculating the reimbursement amount
  • Price model calculations
  • (Pre-launch) Reimbursement price simulations

Operational support

  • Negotiation with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband)
  • Appendices I to III (European prices, expected annual volumes, comparable medicinal products)
  • Simulation of price negotiation ("Mock-ups")
  • Support of arbitation board proceedings

 

Ansprechpartner

 
 
 
 
Dr. Danny Bot
Tel. +49 (40) 41 33 081-22
d.bot(at)ecker-ecker.de
 
 
 
 
Janine Leismann
Tel. +49 (40) 41 33 081-26
j.leismann(at)ecker-ecker.de
created by - sehstrand -